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Abstract
Background: Inflammation plays a critical role in the progression of atherosclerosis, and hyperglycemia is a
common feature in patients with ACS. We investigated the relationship between fasting plasma glucose (FPG)
levels and the levels of the inflammatory factor, myeloperoxidase (MPO), in patients with acute coronary syndrome
(ACS).
Method: A total of 85 patients with no prior history of diabetes mellitus were recruited. The patients were divided
into three groups based on their FPG levels as follows: group A, FPG < 5.6 mmol/l; group B, 5.6 mmol/l ≤ FPG <
6.1 mmol/l; and group C, FPG ≥ 6.1 mmol/l. The FPG concentrations and plasma MPO levels were determined,
coronary angioplasty was performed, and the Gensini scores were used to evaluate the severity of the coronary
lesion. The MPO expression in peripheral blood mononuclear cells (PBMCs) in patients with ACS was determined
using western blot analysis.
Result: The results demonstrated that the levels of FPG were significantly and positively correlated with plasma
MPO levels, Gensini scores, high sensitive C reaction protein(hs-CRP)levels, leukocyte and neutrophils count. In
multivariate regression analyses the FPG levels were positively correlated with plasma MPO levels, Gensini score and
hs-CRP. The plasma MPO levels in the group C [68.68(52.62–91.88) U/L] were significantly higher than in the group
A [63.04(26.18–97.75) U/L] and group B [58.22(23.95–89.54) U/L]. The plasma hs-CRP concentrations are also higher
in group C [42.28 (0.31–169.40) mg/L] than in the group A [12.51(0.28–176.25) mg/L] and group B [14.7 (0.14–89.68)
mg/L].
Conclusion: This study demonstrates that FPG values are positively correlated with plasma MPO levels, suggesting
MPO may play a role in the proatherogenesis of high FPG.
Background
Increased plasma glucose is a common occurrence during
the first few hours of acute coronary syndrome (ACS), not
only in diabetics, but also in non-diabetic patients [1].
Epidemiological studies indicated that hyperglycemia plays
an independent role in cardiovascular disease [2]. Hyper-
glycemia, regardless of diabetic status, remains to be a risk
factor for the short-term mortality of patients with acute
myocardial infarction and treated with percutaneous cor-
onary intervention [3–5], whereas fasting plasma glucose
(FPG) levels are a better predictor of adverse outcomes in
ACS patients during hospitalization than the admission
plasma glucose (APG) level [6]. Several studies showed
that the proatherogenic role is related to the production
of reactive oxygen species [6–8] and platelet dysfunction
[5]. However, the direct influence, if any, of hyperglycemia,
on ACS patients remains unclear.
Myeloperoxidase (MPO) is a type of leukocyte enzyme
that is promptly released after activation. MPO and its
oxidant products have been identified in atherosclerotic
plaques, promoting a number of pathological events that
participate in plaque formation and rupture [9, 10]. In
clinical studies, elevated MPO levels are associated with
an adverse prognosis and the occurrence of major cardio-
vascular events [11–13]; therefore, MPO is also a key
inflammatory factor in the course of the plaque formation
and rupture, similar to CRP. To our knowledge, there is
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no available study about the relationship between the fast-
ing plasma glucose level (FPG) and MPO in patients with
ACS. The objective of this study is to determine whether
the changes in FPG influence MPO.
Methods
Study subjects
A total of 85 patients with acute coronary syndrome,
including acute myocardial infarction and unstable angina,
and no prior history of diabetes mellitus were recruited.
The patients were divided into three groups based on their
FPG levels as follows: group A (n = 33), FPG < 5.6 mmol/l;
group B (n = 23), 5.6 mmol/l ≤ FPG < 6.1 mmol/l; and
group C (n = 29), FPG ≥ 6.1 mmol/l. Unstable angina was
defined as ischemic chest pain at rest, accompanied by
transient ST-T segment depression and/or T-wave inver-
sion within the next 24 h. The diagnosis of acute myocar-
dial infarction was based on a history of ischemic chest
pain >30 min, characteristic ECG changes, and an increase
of creatine kinase activities to at least twice the normal
upper level within 24 h of the pain. The exclusion criteria
includes body temperature >38 °C; inflammatory diseases,
such as infections, malignancies, and autoimmune dis-
eases; human immunodeficiency virus (HIV); impaired
liver function; renal failure; serum total cholesterol con-
centration >7.0 mmol/L; hemoglobin A1c (HbA1c) above
6.5 %; and recent major surgery. Experienced interven-
tional cardiologists performed all revascularization proce-
dures. Coronary angioplasty was performed and stent was
implanted if necessary and the Gensini scores were used
to evaluate the severity of the coronary lesion. The Institu-
tional Ethics Committee of the 2nd Xiangya Hospital of
Central South University approved this study. All of the
subjects have provided written informed consent.
Biochemical analysis
Using standard automated enzymatic methods, a Hitachi
912 automated analyzer, and reagents from the Kamiya
Biomedical Company, the serum triglycerides (TG), total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C), high sensitive C reaction protein (hs-CRP) and
fasting plasma glucose levels (FPG) (FPG was deter-
mined after >8 h of fasting) and liver and renal functions
were determined at the central chemistry laboratory of
our hospital. The LDL-C level was calculated using the
Friedwald formula, and the plasma MPO levels were
measured with an ELASA kit (Jingmei BioTech Co.Ltd).
Peripheral blood mononuclear cells preparation
Peripheral blood mononuclear cells (PBMCs) isolation
was performed using the Ficoll-Hypaque density-
gradient centrifugation method from the patients with
ACS. After centrifugation, buffy coats were collected
and washed in phosphate-buffered saline (PBS; Gibco,
Darmstadt, Germany) for 3 times and suspended at a
concentration of 2 × 106 cells per milliliter with complete
RPMI 1640 medium containing 2 mM l-glutamine, 100
U/mL penicillin, 100 μg/mL streptomycin, 0.05 mM 2-
mercaptoethanol, supplemented with 10 % fetal calf serum
(Gibco, Germany). Cell viability was evaluated using 95 %
by the trypan blue exclusion test. Cells were collected for
MPO protein assays.
Detection of MPO expression in PBMCs by western blot
To determine the expression of MPO in human PBMCs,
immunoblot analysis was performed. Cells (2 × 107) were
lysed with Triton lysis buffer (50 mM Tris-HCL, pH 8.0
containing 150 mM NaCl, 1 % Ttriton X-100, 0.02 % sol-
dium azide, 10 mM EDTA, 10 μg/ml aprotinin, and1μg/
ml aminoethyl benzenesulfonyl fluoride). Protein concen-
trations were determined by Bradford assay. One hundred
micrograms of protein from the cell lysates were loaded
onto a 7.5 % SDS-PAGE gel. After electronphoresis, the
SDS-PAGE separated proteins were transferred to a nitro-
cellulose membrane (Amersham Pharmacia Biotech). The
membrane was blocked with 2.5 % nonfat milk in PBS and
incubated with rabbit antibody against human MPO
(1:200 dilution) in PBS for 2 h. Then the membrane was
incubated with goat anti-rabbit IgG conjugated with
horseradish peroxidase (Santa Cruz, Biotechnology, CA,
USA) at 1:1000 in PBS for 1 h. Blots were processed using
an ECL kit (Santa Cruz) and exposed to X-ray film.
Statistical analyses
All data were tested for normal distribution with
Kolmogorov-Smirnov test and for homogeneity of vari-
ances with Levene’s test. Data are expressed as mean ± SD
or median for parametric and nonparametric data respect-
ively, categorical variables as numbers and percentages.
The baseline characteristics of group categorized by FPG
level were compared by use of ANOVA for continuous
variables and by Kruskal-Wallis Test followed by Mann-
Whitney nonparametric test for noncontinuous variables.
Univariate and multivariate analyses of the effects of the
factors on FPG were performed with linear regression
analyses. Differences were considered statistically signifi-
cant at the 2-sided P < 0.05 level. Statistical analyses were
performed with SPSS statistical software (18.0).
Results
Baseline characteristics of the patients
The clinical characteristics of ACS were shown in Table 1.
Leukocyte count in the group B and C were more than in
the group A. The Gensini scores in the group B and C
were significantly higher than in the group A. There were
no statistically significant differences between the three
groups in the other patient’s characteristics, medication
histories and smoking.
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Correlation analysis FPG with other parameters
Spearman correlation analyses were performed to assess
the relationships at baseline in all patients. The results
demonstrate that FPG were significantly and positively
correlated with plasma MPO levels, Gensini scores, hs-
CRP levels, leukocyte count and neutrophils count
(Table 2). Multivariate regression analyses were further
performed to assess the relationships between the FPG
with these variables and showed that the FPG levels were
still positively correlated with plasma MPO levels, Gensini
score and hs-CRP (Table 3).
Effects of FPG on plasma MPO levels and hs-CRP in
patients
As shown in Figs. 1 and 2, the plasma MPO levels in the
group C [68.68(52.62–91.88) U/L] were significantly
higher than in the group A [63.04(26.18–97.75) U/L] and
group B [58.22(23.95–89.54) U/L]. The plasma hs-CRP
concentrations are also higher in group C [42.28 (0.31–
169.40) mg/L] than in the group A [12.51(0.28–176.25)
mg/L] and group B [14.7 (0.14–89.68) mg/L]. There were
no significantly differences in these two parameters be-
tween in the group A and B.
Effect of FPG on MPO expression of PBMCs in patients
MPO expression in PBMCs was detected by western blot
analysis. As shown in Fig. 3, it was found that FPG had
no effect on MPO expression in PBMCs from patients
with ACS.
Discussion
The blood glucose concentration is closely associated with
cardiovascular diseases and a greater number of adverse
events. The mechanism by which glycemia is associated
with higher mortality remains unclear. Several studies
showed that hyperglycemia is associated with increased
coagulability and oxidative stress and promotes apoptosis
in the rat heart [14–17]. The main finding of present study
is that in patients with ACS, the FPG concentrations are
positively correlated with plasma MPO levels. Further-
more, the plasma MPO levels and hs-CRP concentrations
significantly increase in the highest FPG group (group C).
These results demonstrate that high FPG may promote an
Table 1 Baseline characteristics of the patients
Group A Group B Group C
N = 33 N = 23 N = 29
Age (year) 63 ± 10 68 ± 9 67 ± 10
Male/female(n) 18/15 12/11 20/9
BMI(kg/m2) 23.6 ± 0.4 23.5 ± 0.52 23.6 ± 0.3
Smoking, n (%) 20(61) 13(56) 19(69)
SBP(mmHg) 130 ± 4 127 ± 3 128 ± 3
DBP(mmHg) 76 ± 2 74 ± 2 75 ± 2
Leukocyte ( 109/L) 5.5 ± 1.95 6.7 ± 1.87* 7.18 ± 2.10*
Creatinine (μmol/L) 109.7 ± 9.6 99.38 ± 4.5 99.65 ± 5.88
TG(mmol/L) 2.05 ± 0.25 1.85 ± 0.22 2.8 ± 0.90
TC(mmol/L) 5.05 ± 0.18 4.54 ± 0.18 4.8 ± 0.12
LVEF (%) 0.59 ± .03 0.58 ± 0.02 0.57 ± 0.03
Gensini score 29.7(21.0–56.2) 35.1(23.8–55.0)* 43.6(22.0–56.0)*, **
Medications, n (%)
Aspirin 13 (39) 10 (43) 11 (37)
β-blocker 15 (45) 11 (47) 14 (48)
ACEI/ARB 21 (67) 16 (76) 20 (68)
CCB 7 (22) 4 (19) 5 (17)
Nitrate 21 (63) 16 (69) 18 (62)
Statin 10 (30) 8 (34) 11 (37)
Values are presented as mean ± SD. or n (%) or median
BMI body mass index; SBP systolic blood pressure; DBP diastolic blood
pressure; TG triglyceride; TC total cholesterol; LVEF left ventricular ejection
fraction; ACEI angiotensin-converting enzyme inhibitors; ARB angiotensin II
receptor blockers; CCB calcium channels blockers
*P < 0.05 when compared with Group A; ** P < 0.05 when compared with
Group B
Table 3 Multiple stepwise regression analysis of the correlation












Constant 2.339 0.615 3.802 0.000
Hs-CRP 0.014 0.004 0.306 3.588 0.001
MPO 0.024 0.005 0.346 4.439 0.000
Gensini score 0.051 0.015 0.279 3.359 0.001




Gensini score 0.568 0.000
Leukocyte count 0.353 0.001










MPO myeloperoxidase; hs-CRP high sensitive C reaction protein; other
abbreviations are as shown in Table 1
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inflammatory reaction during ACS, leading to an increase
of plasma MPO levels, and finally causing plaque forma-
tion and rupture. As we all known, PBMCs are more
important in atherosclerosis. However, the present study
did not shown the significant effects of FPG on the MPO
expression of PBMCs, indicating that FPG may play a
role in the acute inflammatory reaction in patients
with ACS via another type of leukocyte (maybe neu-
trophil). Being the most abundant leukocyte in the
circulation, neutrophil received little attention in the
Fig. 2 The plasma hs-CRP levels in the three groups. * p < 0.05 when compared to Group A or Group B
Fig. 1 The plasma MPO levels in the three groups. * p < 0.05 when compared to Group A or Group B
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pathophysiology of atherosclerosis, but recent ad-
vances pointed out a contributory role of neutrophils
during atherogenesis and plaque destabilization [18–
20]. Several proteins expressed and released by neu-
trophils emerged as possible biomarkers. MPO was
abundantly expressed in neutrophil granules and par-
tially released on neutrophils activation, leading to the
plaque instability and vulnerability. In our study, the
result also showed the positive association between
the numbers of neutrophils and the FPG concentra-
tions, this was consistent with the previous studies
[19, 21–23].
In this study, we evaluated the relationship between
the severity of coronary atherosclerosis and FPG, and
the results showed that the FPG concentration increased
with increasing Gensini score, suggesting that the FPG is
also an indicator of the severity of the coronary artery
lesion, which is consistent with the previous investiga-
tions [24, 25].
The majority of published studies evaluated the influ-
ence of APG on the prognosis of patients with ACS
[26–28]. However, it is suggested that FPG may play a
determining role. Otten et al. [29] showed that FPG is
an independent predictor of adverse events in patients
with ACS. In addition, Ravid et al. [30] and Soler et al.
[31] demonstrated that FPG is a significant risk factor,
and David Vivas et al. [6] have suggested that the FPG
concentration is a better indicator of metabolic status
than APG during the first few days of ACS. In addition,
a significant relationship between high FPG and mortality
within 30 days in non-diabetic patients with ACS was
found by Suleiman et al. [32], with death usually occurring
in patients with high FPG and normal APG values, or in
those with high FPG and high APG, rather than in those
with normal FPG. Moreover, for patients presenting an un-
favorable clinical course during the first few hours of ACS,
an increase in FPG may reflect a worse metabolic state and
may be associated with more severe situations [33–35];
therefore, FPG may better represent the metabolic status of
the patient with ACS. For clinicians caring for a patient
with ACS, it is important to define the target below which
the blood glucose levels should be maintained. The results
of the study show that when the FPG levels are greater than
6.1 mmol/l (group C), the MPO levels and the hs-CRP
levels are increased, indicating that clinicians may choose
appropriate FPG values to avoid excessive inflammation in
patients with ACS.
Limitations
An important limitation of this study is that there was a
small number patients, no patients were administered an
OGTT. As a result, it cannot be determined whether pa-
tients with no prior history of diabetes will become dia-
betics during observation.
Fig. 3 The MPO expression of PBMCs in the three groups. a Detection of MPO expression in cultured PBMCs from patients with ACS by Western
blot analysis; b Effect of FPG on MPO expression of PBMCs, MPO expression is expressed as absorbance ratio of MPO product to β-actin product
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Conclusions
This study demonstrates that FPG values are positively
correlated with plasma MPO levels, suggesting MPO may
play a role in the proatherogenesis of high FPG. The exact
roles of high FPG, MPO and their relation in the athero-
sclerosis have been completely clarified, it needs further
investigation.
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